scholarly journals Prognostic Value of Vimentin Is Associated With Immunosuppression in Metastatic Renal Cell Carcinoma

2020 ◽  
Vol 10 ◽  
Author(s):  
Jia xi Yao ◽  
Xiang Chen ◽  
Yan jun Zhu ◽  
Hang Wang ◽  
Xiao yi Hu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Prognostic Value

Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 626-626 ◽  
Author(s):  
Dominick Bosse ◽  
Wanling Xie ◽  
Aly-Khan A. Lalani ◽  
Guillermo de Velasco ◽  
Martin Henner Voss ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Prognostic Value ◽  
Kinase Inhibitors ◽  
Cox Regression ◽  
Risk Groups ◽  
Genomic Alterations ◽  
Endothelial Growth Factor

626 Background: The IMDC risk score is a valid and simple tool to prognosticate patients (pts) with metastatic renal cell carcinoma (mRCC). Some non-VHL common genomic alterations may be associated with outcomes. We therefore assessed the prognostic value of most commonly mutated genes in mRCC beside VHL overall, and within IMDC risk groups. Methods: We identified patients treated at Dana-Farber Cancer Institute (n = 65) or part of TCGA (n = 33) who had genomic data available and were treated with first line vascular endothelial growth factor tyrosine kinase inhibitors. Information on genomic alterations (GA) focused on PBRM1, BAP1, SETD2, KDM5C and TP53 was extracted. Cox regression was performed to assess the association of each GA with overall survival (OS), adjusting for IMDC risk groups and age. Results: Overall, 98 pts were identified. 96/98 pts had clear-cell histology. Pts distribution by IMDC risk groups was: 7% good, 58% intermediate, 27% poor and 8% unknown. Mutation rates were 27% PBRM1, 17% BAP1, 29% SETD2, 9% KDM5C and 8% TP53. In multivariable models, there was an association between GA and worse OS for BAP1 and BAP1 or TP53 combined (Table). When stratified by IMDC risk groups, GA in BAP1 or TP53 was associated with shorter median OS in poor risk pts [12.1 mo (95%CI 8.3- 24.0) v. 27.6 mo (95%CI 18.9- 53.4), aHR 4.64 (95%CI 1.32-16.4), p = 0.017] and a trend toward worse median OS in intermediate risk pts [20.5 mo (95%CI 7.4-54.6) v. 36.3 mo (95%CI 21.1, NR), aHR 2.11 (95%CI 0.94-4.74)] compared to pts without GA in BAP1 or TP53. Too few death events were observed in good risk pts to assess the prognostic value of GA in BAP1 or TP53. Conclusions: GA in BAP1 or TP53 are prognostic in mRCC and further discriminate pts with distinct outcomes within IMDC risk groups. Validation in larger dataset is ongoing. [Table: see text]

Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib

2016 ◽  
Vol 12 (15) ◽  
pp. 1783-1793
Author(s):  
Weijie Gu ◽  
Beihe Wang ◽  
Hualei Gan ◽  
Yao Zhu ◽  
Hongkai Wang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Prognostic Value ◽  
Primary Lesion ◽  
Pathological Features

scholarly journals Prognostic value of lymphocyte-to-monocyte ratio previously determined to surgery in patients with non-metastatic renal cell carcinoma

Medicine ◽  
2021 ◽  
Vol 100 (3) ◽  
pp. e24152
Author(s):  
Dario Garcia-Rojo ◽  
Angel Prera ◽  
Jesus Muñoz-Rodriguez ◽  
Joan Carles Oliva ◽  
Arturo Dominguez ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Prognostic Value ◽  
Lymphocyte To Monocyte Ratio
Sign in / Sign up

Export Citation Format

Share Document